Role of sequencing in therapy selection

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue SUPPL. 1, 2002, Pages

  Keiser, Philip ^a  

^a NONE   (United States)

Author keywords

Antiretroviral sequencing; Highly active antiretroviral therapy (HAART) sequencing options; Sequencing decisions in antiretroviral therapy (ART)

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL; CROSS RESISTANCE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG TOXICITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEQUENTIAL ANALYSIS; TREATMENT FAILURE; TREATMENT PLANNING; VIRUS LOAD;

EID: 0036471410     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200202011-00004     Document Type: Review

References (30)

1. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
2. HIV-1 drug resistance in newly infected individuals
3. Differences in protease inhibitor (PI) phenotypic susceptibility after failure of the first PI-containing regimen
4. Sequencing of protease inhibitor therapy: Insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors
5. Antiretroviral drug susceptibility and response to initial therapy among recently HIV-infected subjects in North America
6. Three-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
7. ABT-378/ritonavir (ABT-378/r) versus nelfinavir in antiretroviral naive subjects: Week 48 comparison in a phase III blinded randomized clinical trial
8. Absence of resistance to Kaletra (ABT-378/r) observed through 48 weeks of therapy in antiretroviral-naive subjects
9. Genotypic correlates of reduced in vitro susceptibility to ABT-378 in HIV isolates from patients failing protease inhibitor therapy
10. Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to ABT-378
11. Differential impact of specific key mutations in HIV protease on phenotypic susceptibility to amprenavir and lopinavir
12. Plasma trough levels correlate with distinct genetic mechanisms during the development of amprenavir resistance
13. Longer time-to-treatment failure and durability of response with efavirenz + ZDV + 3TC: First analysis of full 1266 patient cohort from Study 006
14. Low two-year risk of virologic failure with first regimen HAART
15. Impact of directly observed therapy on outcomes in HIV clinical trials
16. Successful substitution of protease inhibitors with efavirenz (EFV) in patients with undetectable viral loads-a prospective, randomized, multicenter, open-label study (DMP 049)
17. Nonnucleoside reverse transcriptase inhibitor resistance
18. Non-nucleoside reverse transcriptase inhibitor viral hypersensitivity is common and improves short-term virological response
19. Abacavir-lamivudinezidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
20. Potential advantages of a compact triple nucleoside regimen: Efficacy and adherence with Combivir/abacavir versus Combivir/indinavir in an open-label randomised comparative study (CNAB3014)
21. Abacavir/Combivir versus indinavir/Combivir in therapynaive adults (CNA3014). 48-week efficacy, safety and adherence results from an open-label randomized equivalence study
22. A novel use of abacavir to simplify therapy in PI experienced patients successfully treated with HAART CNA30017
23. Reverse transcriptase (RT) mutation patterns from ZDV-naive subjects failing d4Tcontaining regimens
24. Determination of a clinically relevant phenotype resistance "cutoff" for abacavir using the PhenoSense assay
25. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM
26. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: A comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val
27. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy
28. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase